LENSAR

LENSAR Forward P/E

The Forward P/E Ratio of LENSAR (LNSR) as of Oct 21, 2026 is -4.26. In the previous year, Forward P/E Ratio was -4.65 — a change of -8.39% (higher).

Forward P/E

-4.26

YoY

-8.39%

Last updated:

Forward P/E Ratio of LENSAR is 2025 -4.26 . Forward P/E Ratio of LENSAR was 2024 -4.65 . It decreases by -8.39% higher compared to the previous year.

The LENSAR Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2018
-11.60 USD
Jan 1, 2019
-9.97 USD
Jan 1, 2020
-7.39 USD
Jan 1, 2021
-7.45 USD
Jan 1, 2022
-7.34 USD
Jan 1, 2023
-10.16 USD
Jan 1, 2024
-4.65 USD
Jan 1, 2025
-4.26 USD
The LENSAR Forward P/E history
YEARForward P/EYoY
-4.26-8.39%
-4.65-54.20%
-10.16+38.46%
-7.34-1.57%
-7.45+0.88%
-7.39-25.88%
-9.97-14.08%
-11.60—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

LENSAR Stock analysis

What does LENSAR do? LENSAR, Inc. generates revenue through the sale of its femtosecond laser systems, specifically the LENSAR Laser System with Streamline IV and IntelliAxis, and the ALLY Adaptive Cataract Treatment System. The LENSAR Laser System includes disposable patient interface device kits as consumables, which contribute to recurring revenue. Surgeons and ophthalmic clinics purchasing these systems form the primary customer segment, utilizing the technology for cataract surgery and corneal astigmatism management. The company's focus on proprietary technologies ensures differentiation in the medical device market. The ALLY System is marketed as a compact solution for femtosecond laser assisted cataract procedures, designed to streamline surgical workflows within a single operating room. Its product portfolio emphasizes integrated features that enhance visual outcomes for patients. The consumable components, such as the disposable patient interface device kits, support ongoing revenue streams alongside the initial system sales. These offerings target healthcare providers seeking advanced surgical tools for refractive cataract surgery. LENSAR's business model relies on selling high-precision medical devices to specialized healthcare facilities. The LENSAR Laser System and ALLY System are positioned as premium solutions for cataract treatment, with the consumables providing sustained revenue opportunities. The company's product development centers around improving surgical efficiency and patient visual results through its patented technologies. LENSAR is one of the most popular companies on Eulerpool.

Frequently Asked Questions about LENSAR stock

Forward P/E Ratio of LENSAR is -4.26 in 2025.

Forward P/E Ratio of LENSAR changed from -4.65 to -4.26, representing a -8.39% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio LENSAR since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's LENSAR with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — LENSAR

All Key Metrics — LENSAR